Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nab-paclitaxel + Gemcitabine + Cisplatin in Unresectable Biliary Tract Cancer
NCT02632305Phase 2Active, not recruiting
- Sponsor
- American Health Staffing Group
- Start
- Jul 2016
- Primary completion
- Dec 2026
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel in biliary tract cancer (BTC), sponsored by American Health Staffing Group. Primary endpoint: Overall Response Rate at 1 year. Started Jul 2016; status: active, not recruiting.
02
Drugs
paclitaxel
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT02632305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02632305.